Michael Levidy, MD, a researcher at Hershey, Pa.-based Penn State Health, led the study using a database with CPT and ICD codes to identify patients with Type 2 diabetes who underwent tibiotalar fusion, subtalar fusion or triple arthrodesis between 2005 and 2024.
Researchers put patients into two propensity-matched cohorts of 708 patients each, depending on whether they were prescribed GLP-1s within a year prior to surgery.
Outcome measures included one-year postoperative infection rates and pseudoarthrosis rates.
The study found that patients who underwent tibiotalar fusions had a decrease in one-year postoperative pseudoarthrosis rates, while postoperative infection rates increased at one year in patients who underwent either tibiotalar fusions or tarsal fusions.
Patients treated with GLP-1 agonists had a significantly higher postoperative infection rate of 9% versus 5.6% in the patients not taking GLP-1 agonists.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
